CSL Behring Plasma Product Transition
Under the National Fractionation Agreement for Australia in place between the National Blood Authority and CSL Behring, CSL Behring has been investing in new facilities at its manufacturing site at Broadmeadows in Victoria to provide expanded capacity for processing Australia’s growing annual domestic plasma collections.
CSL Behring, Australia’s chosen national plasma fractionator and manufacturer, is transitioning five Australian domestic plasma products to new, purpose-built manufacturing facilities in Broadmeadows, Victoria. These plasma products will continue to be manufactured in Australia from plasma collected onshore by the Australian Red Cross Lifeblood but will be manufactured using CSL Behring’s global manufacturing processes. As per the current products, the new products will comply with the safety and efficacy requirements set by the Therapeutic Goods Administration.
Below you can access information on specific products that are being transitioned
Find out more about the transition from Albumex® to AlbuRex® AU.
Find out more about the transition from Intragam® to Privigen® AU and Evogam® to Hizentra® AU.